DALLAS, April 29, 2025 — Glucagon-like peptide-1/gastric inhibitory polypeptide (GLP-1/GIP) agonists — originally developed to treat people with diabetes and obesity — are showing promise for ...

The sympathetic nervous system (SNS) plays a crucial role in the regulation of cardiovascular function, mediating rapid adjustments in heart rate and arterial blood pressure during stress, physical ...

The UC Davis Innovation Institute for Food and Health recently hosted scientists, physicians and industry experts to discuss how drugs based on GLP-1 are transforming treatment for obesity, diabetes ...

Washington, D.C. – May 1, 2025 – New findings from multiple studies demonstrate that glucagon-like peptide-1 receptor agonists (GLP-1RAs), a class of medications used to treat type 2 diabetes, play a ...

Public interest in drugs known as glucagon-like peptide-1 receptor agonists, also called GLP-1 RAs, has surged in recent years, with popular types like semaglutide (sold under brand names like Ozempic ...

After a century of progress that cut deaths from cardiovascular disease in half, momentum has stalled. Heart disease and stroke remain the leading causes of death worldwide, mortality rates are ...

Despite a significant decline in cardiovascular disease risk for people with type 1 diabetes over time, the risk remains higher than that of the general population, new data from Finland show.

In a multicenter, randomized, double-blind, placebo-controlled, noninferiority trial, we enrolled 5246 men 45 to 80 years of age who had preexisting or a high risk of cardiovascular disease and who ...